Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Tacalyx, a Germany-based cancer therapeutics developer spun out of Max Planck Institute (MPI) of Colloids and Interfaces, today secured €7m ($7.7m) of seed funding from investors co-led by Kurma Partners and Boehringer Ingelheim Venture Fund, part of pharmaceutical firm Boehringer Ingelheim. Public-private partnership High-Tech Gründerfonds also contributed capital alongside Idinvest Partners, Coparion and Creathor Ventures.…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.